Clinical trials: Heart Failure With Preserved Ejection Fraction
Obesity, Heart Failure
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body…
- Trial name
- HF-POLARIS (NCT07567001)
- Testing
- NNC0487-0111
- Where
- 838 sites in United States, Argentina and 25 more
- Volunteers
- 5,610 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-TIRZSEMA (NCT06914141)
- Testing
- Tirzepatide, Semaglutide
- Where
- United States
- Volunteers
- 28,118 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure, Heart Failure, Diastolic
Impact of Beta-blockers on Physical Function in HFpEF
The purpose of this study is to understand the impact of beta-blockers on physical function in older adults with heart failure. We will achieve this objective by conducting N-of-1 trials.
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure
- Trial name
- NCT04767061
- Testing
- Beta blockers
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Weill Medical College of Cornell University
Heart Failure With Preserved Ejection Fraction, Diastolic Dysfunction
Sex Related Differences in Cardiac Function
The aim of the study is to investigate sex-specific differences in LV and RV function (systolic and diastolic) with regarding the development and progression of heart failure with preserved ejection fraction based on a…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Diastolic Dysfunction, Systolic Dysfunction
- Trial name
- NCT05796050
- Where
- Germany
- Volunteers
- 6,000 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Heart Failure
Development of Specific Diagnostic Tools for Cardiac Insufficiency With Preserved Ejection Fraction
The MeDIAGSTOLE project aims to develop diagnostic tools for heart failure with preserved ejection fraction (IC / FEp), a pathology that is difficult to diagnose and to manage clinically in the absence of targeted treatment .
- Trial name
- MeDIAGSTOLE (NCT04699890)
- Testing
- Blood sampling, questionnaires and specific exams
- Where
- France
- Volunteers
- 91 people
- Sponsor
- University Hospital, Montpellier
Heart Failure
NoYA RAISE Trial II (Radiofrequency Ablation-Based Interatrial Shunt for Heart Failure)
A Prospective, Multiple Center, and Objective Performance Criteria Study to Evaluate the NoYA™ Radiofrequency Interatrial Shunt System manufactured by NoYA Medtech (Hangzhou) Co., Ltd.
- Trial name
- NCT05375110
- Testing
- NoYA™ Radiofrequency Interatrial Shunt System
- Where
- 31 sites in China
- Volunteers
- 120 people
- Sponsor
- Hangzhou NOYA MedTech Co. Ltm.
Type 2 Diabetes Mellitus, Heart Failure
ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure
This study aims to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with type 2 diabetes and heart failure (T2D-HF).
- Trial name
- ERADICATE-HF (NCT03416270)
- Testing
- Ertugliflozin
- Where
- 3 sites in Canada, Netherlands
- Volunteers
- 34 people
- Sponsor
- University Health Network, Toronto
Heart Failure and Preserved Ejection Fraction, Obesity (Disorder)
OBESE-HFpEF: Towards Preventing Obesity Related HFpEF
Obesity, severe overweight, is a growing problem worldwide and increases the risk of heart failure, especially a type called heart failure with preserved ejection fraction (HFpEF). In HFpEF, the heart becomes stiffer.
- Conditions
- Heart Failure and Preserved Ejection Fraction, Obesity (Disorder), Heart Failure
- Trial name
- OBESE-HFpEF (NCT07539766)
- Where
- Netherlands
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Zuyderland Medisch Centrum
Heart Failure, Heart Failure With Preserved Ejection Fraction
Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization…
- Trial name
- NCT06517186
- Where
- 6 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Heart Failure, Diabete Type 2
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs
This clinical study aims to improve the diagnosis and treatment of cardiovascular diseases in Kazakhstan by Implementing Metabolic Correction with Glucagon-Like Peptide-1 (GLP-1).
- Conditions
- Heart Failure, Diabete Type 2, Arterial Hypertension
- Trial name
- ICDDTKZ26 (NCT07303556)
- Testing
- Tirzepatide (Mounjaro), dapagliflozin, empagliflozin, metformin
- Where
- Kazakhstan
- Volunteers
- 120 people
- Sponsor
- Nazarbayev University
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Trial name
- MARITIME-HF (NCT07037459)
- Testing
- Maridebart cafraglutide
- Where
- 657 sites in United States, Argentina and 32 more
- Volunteers
- 5,056 people
- Sponsor
- Amgen
Heart Failure With Preserved Ejection Fraction
Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF
RESPOND-HF is a prospective, multi-center, non-significant risk pilot study with cross-over design. The purpose of the study is to investigate if rate adaptive pacing has the potential to provide benefit to HF patients with…
- Trial name
- RESPOND-HF (NCT03160625)
- Testing
- Rate Adaptive Pacing
- Where
- 5 sites in United States
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Preserved Ejection Fraction (HFPEF)
Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction
Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours
- Trial name
- NCT07634640
- Testing
- Ferumoxytol infusion
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Florida
Heart Failure With Preserved Ejection Fraction (HFPEF)
The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood…
- Trial name
- EAT HFpEF (NCT06768437)
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- University of Leicester
Atrial Fibrillation (AF), Pacemaker Therapy
Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF
This prospective, randomized controlled trial aims to evaluate the effect of left bundle branch pacing (LBBP) compared with conventional right ventricular (RV) pacing on the cumulative duration (total time) of atrial high-rate…
- Conditions
- Atrial Fibrillation (AF), Pacemaker Therapy, Atrioventricular Block, Preserved Ejection Fraction
- Trial name
- LBBP-AHRE (NCT07250529)
- Testing
- Right Ventricular Pacing, Left Bundle Branch Pacing
- Where
- Greece
- Volunteers
- 244 people
- Sponsor
- University Hospital of Patras
Heart Failure, Diastolic
Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction
A 35-week, single-center, prospective, double-blind, controlled, randomized, 2x2 crossover, interventional Phase II study, investigating the effect of treatment with dapagliflozin 10mg od on Left Ventricular distensibility in…
- Trial name
- STADIA-HFpEF (NCT04475042)
- Testing
- Dapagliflozin
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Mariëlle Scheffer
Heart Failure With Preserved Ejection Fraction
Transitions of Care Clinic (TOCC)
The transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital.
- Trial name
- NCT06937827
- Testing
- HF Kit and Follow-ups
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Hackensack Meridian Health
Heart Failure NYHA Class II, Heart Failure NYHA Class III
CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis
The study aims to test the diagnostic accuracy of T1 mapping for the diagnosis of cardiac amyloidosis prospectively. The hypothesis is that T1 mapping in older patients with symptomatic heart failure, increased LV wall thickness…
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure With Preserved Ejection Fraction
- Trial name
- CMR for CA (NCT04862273)
- Testing
- Native T1 CMR, Web-based ATTR probability estimator (Pfizer, New York), 99mTc-DPD scintigraphy
- Where
- Germany
- Volunteers
- 112 people
- Sponsor
- University of Leipzig
Heart Failure
A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects
AZD9977 is an oral, selective mineralocorticoid receptor (MR) modulator. AZD9977 is a partial antagonist and partial agonist in reporter gene assays and has a different interaction pattern with the MR compared to eplerenone.
- Trial name
- NCT03804645
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HFpEF - Heart Failure With Preserved Ejection Fraction
HEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection Fraction
The goal of this study is to learn more about patients with heart failure with preserved ejection fraction (HFpEF) and exercise.
- Trial name
- NCT05784753
- Testing
- HEART Camp, HEART Camp Connect
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Nebraska